2.65 -0.09 (-3.28%) | 02-06 10:37 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 3.28 ![]() |
1-year : | 3.62 ![]() |
Resists | First : | 2.81 ![]() |
Second : | 3.1 ![]() |
Pivot price | 2.57 ![]() |
|||
Supports | First : | 2.34 ![]() |
Second : | 1.95 ![]() |
MAs | MA(5) : | 2.67 ![]() |
MA(20) : | 2.55 ![]() |
MA(100) : | 3.82 ![]() |
MA(250) : | 4.32 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 74.4 ![]() |
D(3) : | 69.1 ![]() |
RSI | RSI(14): 47.5 ![]() |
|||
52-week | High : | 6.4 | Low : | 2.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TSVT ] has closed below upper band by 22.0%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.84 - 2.85 | 2.85 - 2.86 |
Low: | 2.68 - 2.69 | 2.69 - 2.7 |
Close: | 2.72 - 2.74 | 2.74 - 2.76 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Thu, 06 Feb 2025
Abecma Sales Hit $242M: 2seventy bio's Path to Profitability Takes Shape - StockTitan
Mon, 20 Jan 2025
2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sun, 19 Jan 2025
Barclays PLC Has $380,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT) - MarketBeat
Tue, 31 Dec 2024
2seventy bio, Inc.'s (NASDAQ:TSVT) 28% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Fri, 15 Nov 2024
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St
Thu, 14 Nov 2024
2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 52 (M) |
Shares Float | 50 (M) |
Held by Insiders | 4.2 (%) |
Held by Institutions | 90.5 (%) |
Shares Short | 5,080 (K) |
Shares Short P.Month | 4,680 (K) |
EPS | -1.84 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.55 |
Profit Margin | -207.3 % |
Operating Margin | -99.3 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 12.5 % |
Gross Profit (p.s.) | -1.76 |
Sales Per Share | 0.88 |
EBITDA (p.s.) | -2.61 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -1.47 |
PEG Ratio | 0 |
Price to Book value | 0.58 |
Price to Sales | 3.03 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |